The health minister is to press the Belfast Trust on its reasons for not making available a new drug to treat muscular dystrophy.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

A 12-year-old boy with a severe form of muscular dystrophy has said it is "cruel" that a new drug is not being made available ...

Five oculopharyngeal muscular dystrophy (OPMD) patients have now been treated with the gene therapy candidate BB-301 in a ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics And Genomics ...

Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, has been working with national and ...

Caleb Kasner and his brother Duncan Kasner move around a little differently than average kids. The two brothers have Duchenne ...

The Galesburg Fire Department raised more than $31,100 for the Muscular Dystrophy Association. The department took second ...

It turns out that being able to carry 75% of your body weight for a minute—sometimes referred to as “the carry test”—can tell ...

Enrollment of healthy volunteers for a Phase 1 trial testing Duchenne muscular dystrophy (DMD) treatment candidate SAT-3247 ...